Abstracts tagged "Sjogren’s syndrome and auto-immunity"

Abstract Number: 2174 • 2012 ACR/ARHP Annual Meeting
Natural History of Sjögren’s Syndrome Phenotypic Features in the Sjögren’s International Collaborative Clinical Alliance Registry
Caroline Shiboski¹, Alan N. Baer², Mi Y. Lam¹, Stephen Challacombe³, Hector Lanfranchi⁴, Morten Schiødt⁵, Hisanori Umehara⁶, Frederick B. Vivino⁷, Yan Zhao⁸, Yi Dong⁸, Bruce W. Kirkham⁹, Kenneth E. Sack¹⁰, Susumu Sugai¹¹, Cristina F. Vollenweider¹², Wen Zhang⁸, John S. Greenspan¹, Troy Daniels¹³, Lindsey A. Criswell¹⁴ and Sjögren's International Collaborative Clinical Alliance¹⁵, ¹Orofacial Sciences, University of California San Francisco, San Francisco, CA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Kings College London, London, United Kingdom, ⁴University of Buenos Aires, Buenos Aires, Argentina, ⁵Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, ⁶Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, ⁷Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ⁸Rheumatology, PUMCH, Bejing, China, ⁹Rheum Dept/ Guys Hospital, Guys Hospital, London, United Kingdom, ¹⁰Dept of Medicine/Box0326, Univ of Calif-San Francisco, San Francisco, CA, ¹¹Kanazawa Medical University, Ishikawa, Japan, ¹²Rheumatology, German Hospital, Buenos Aires, Argentina, ¹³Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, ¹⁴Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹⁵Orofacial Sciences, University of California San Francisco, University of California San Francisco, CA
Background/Purpose: Sjögren’s syndrome (SS) is known to be a relatively stable or slowly progressing disease, however, few studies have actually followed patients over time while…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].